Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 648

• Price / Volume Information    Yesterday's Closing Price: $4.62 Daily Weekly Monthly 20 Day Moving Average: 778,187 shares Shares Outstanding: 127.86 (millions) Market Capitalization: $590.73 (millions) Beta: 1.33 52 Week High: $7.30 52 Week Low: $2.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.00% 16.86% 12 Week 15.21% 10.44% Year To Date -28.81% -37.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd. - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President; Chief Executive Officer and Director William McCombe - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Don Hardison - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 127.86 Most Recent Split Date: (:1) Beta: 1.33 Market Capitalization: $590.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.55 Price/Cash Flow: 133.13 Price / Sales: 3.00 EPS Growth vs. Year Ago Period: -500.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 1.54% vs. Previous Quarter: 14.67% ROE 09/30/25 - -3.35 06/30/25 - -1.66 03/31/25 - -2.90 ROA 09/30/25 - -2.60 06/30/25 - -1.30 03/31/25 - -2.30 Current Ratio 09/30/25 - 5.17 06/30/25 - 5.22 03/31/25 - 5.62 Quick Ratio 09/30/25 - 4.48 06/30/25 - 4.55 03/31/25 - 4.95 Operating Margin 09/30/25 - -6.51 06/30/25 - -3.27 03/31/25 - -5.71 Net Margin 09/30/25 - -6.51 06/30/25 - -3.27 03/31/25 - -5.71 Pre-Tax Margin 09/30/25 - -7.87 06/30/25 - -3.86 03/31/25 - -4.05 Book Value 09/30/25 - 2.98 06/30/25 - 2.98 03/31/25 - 2.98 Inventory Turnover 09/30/25 - 1.92 06/30/25 - 1.93 03/31/25 - 1.91 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.17 06/30/25 - 0.21 03/31/25 - 0.24

Powered by Zacks Investment Research ©